Dr Winfried März
Disclosure details
Dr. März reports grants and personal fees from AMGEN, Sanofi, Amryt Pharmaceuticals, Abbott Diagnostics, Akzea Therapeutics, Novartis Pharma GmbH, and SOBIClinical Institute of Medical and Chemical Laboratory Analysis, Medical University of Graz, Austria
Medical Clinic V, Medical Faculty Mannheim, University of Heidelberg, Germany
SYNLAB Academy, SYNLAB Holding Deutschland GmbH, Mannheim and Augsburg, Germany
Dr März has a strong background in clinical and laboratory research. He received his training in laboratory medicine at the Johann Wolfgang Goethe University in Frankfurt, Germany, and his habilitation at the Albert Ludwigs University in Freiburg, Germany.
He is a retired full professorship at the Clinical Institute of Medical and Chemical Laboratory Diagnostics at the Medical University Graz, Austria, and is a working group leader at Medical Clinic V (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Germany. He is also the Director of Academy and Business Development Manager at SYNLAB Germany.
With more than 900 publications listed on PubMed (and approximately 1300 on the Web of Science) in all top-ranked cardiovascular journals and over 40.000 citations he is among the most influential European researchers. For many years, he has been the leading scientist in laboratory medicine in the German speaking countries (DACH) and is among the most frequently cited scientists in the fields of genetics, cardiology, and endocrinology.
Dr März is the principal investigator of the Ludwigshafen Risk Factor and Cardiovascular Health Study (LURIC) and has been a member of the steering committee of the 4D trial (Die Deutsche Diabetes Dialyse Studie). His research has been funded by the European Commission, the Wissenschaftsinitiative Oberrhein, the German Ministry of Education and Research, the German Ministry of Economy, and by major research grants from the pharmaceutical industry.
The scientific interest of Dr März has for a long time been in rare disorders of lipid metabolism, epidemiology, atherosclerosis, and prevention. He very recently and successfully set up the largest registry for familial hypercholesterolemia (FH) in Germany ((CaReHigh) www.dach-praevention.eu/familiaere-hypercholesterinaemie/care-high-kaska-denscreening/) which has by now recruited 3500 FH patients and has become the German branch of the European Atherosclerosis Society FH Study Collaboration.
